Literature DB >> 21840116

Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography.

Patrizio Rigatti1, Nazareno Suardi, Alberto Briganti, Luigi F Da Pozzo, Manuela Tutolo, Luca Villa, Andrea Gallina, Umberto Capitanio, Firas Abdollah, Vincenzo Scattoni, Renzo Colombo, Massimo Freschi, Maria Picchio, Cristina Messa, Giorgio Guazzoni, Francesco Montorsi.   

Abstract

BACKGROUND: The management of patients with clinical recurrence of prostate cancer after radical prostatectomy (RP) remains challenging.
OBJECTIVE: To determine whether the removal of positive lymph nodes at [11C]choline positron emission tomography/computed tomography (PET/CT) scan may have an impact on the prognosis of patients with biochemical recurrence (BCR) and nodal recurrence after RP. DESIGN, SETTING, AND PARTICIPANTS: Prospective analysis of 72 patients affected by BCR after RP associated with a nodal pathologic [11C]choline PET/CT scan. INTERVENTION: Patients underwent salvage lymph node dissection (LND). MEASUREMENTS: Biochemical response (BR) to treatment was defined as prostate-specific antigen (PSA) <0.2 ng/ml at 40 d after salvage LND. Kaplan-Meier and Cox regression analyses addressed time to and predictors of clinical recurrence (CR) after salvage LND, respectively. RESULTS AND LIMITATIONS: Overall, 56.9% of patients achieved BR. Mean and median follow-up after LND were 39.4 and 39.8 mo, respectively. The 5-yr BCR-free survival rate was 19%. Preoperative PSA <4 ng/ml (hazard ratio [HR]: 0.12; p = 0.005), time to BCR <24 mo (HR: 7.52; p = 0.005), and negative lymph nodes at previous RP (HR: 0.19; p=0.04) represented independent predictors of BR. Overall, 5-yr CR-free and cancer-specific survival were 34% and 75%, respectively. At multivariable analyses, only PSA >4 ng/ml (HR: 2.13; p=0.03) and the presence of retroperitoneal uptake at PET/CT scan (HR=2.92; p=0.004) represented independent preoperative predictors of CR. Similarly, the presence of pathologic nodes in the retroperitoneum (HR: 2.78; p=0.02), higher number of positive lymph nodes (HR: 1.04; p=0.006), and complete BR to salvage LND (HR: 0.31; p=0.002) represented postoperative independent predictors of CR. Main limitations consisted of the lack of a control group and the heterogeneity of patients included in the analyses.
CONCLUSIONS: Salvage LND is feasible in patients with BCR after RP and nodal pathologic uptake at [11C]choline PET/CT scan. Biochemical response after surgery can be achieved in a consistent proportion of patients. Although most patients invariably progressed to BCR after surgery at longer follow-up, 35% of patients showed the absence of CR at 5 yr.
Copyright © 2011. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21840116     DOI: 10.1016/j.eururo.2011.07.060

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  57 in total

1.  Clinical impact of 18F-choline PET/CT in patients with recurrent prostate cancer.

Authors:  Jan D Soyka; Marco A Muster; Daniel T Schmid; Burkhardt Seifert; Ulrike Schick; Raymond Miralbell; Sandra Jorcano; Kathrin Zaugg; Hans-Helge Seifert; Patrick Veit-Haibach; Klaus Strobel; Niklaus G Schaefer; Daniela B Husarik; Thomas F Hany
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-03-14       Impact factor: 9.236

2.  Writing PET into existence.

Authors:  A Chiti; M Kirienko; E Incerti; M Picchio
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-09-27       Impact factor: 9.236

3.  Furosemide diminishes ¹⁸F-fluoroethylcholine uptake in prostate cancer in vivo.

Authors:  H Christian Rischke; Teresa Beck; Werner Vach; Gesche Wieser; Anca L Grosu; Wolfgang Schultze-Seemann; Philipp T Meyer; Cordula A Jilg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-06-21       Impact factor: 9.236

4.  Prostate cancer: The role of local therapy for metastatic prostate cancer.

Authors:  Lorenzo Tosco; Hendrik Van Poppel
Journal:  Nat Rev Urol       Date:  2014-02-25       Impact factor: 14.432

Review 5.  PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies.

Authors:  Giampiero Giovacchini; Elisabetta Giovannini; Rossella Leoncini; Mattia Riondato; Andrea Ciarmiello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-14       Impact factor: 9.236

6.  [When is surgical treatment indicated in metastatic prostate cancer and what is the scientific rationale?]

Authors:  A Kretschmer; A Herlemann; C G Stief; C Gratzke
Journal:  Urologe A       Date:  2017-05       Impact factor: 0.639

7.  Oncological outcome of patients treated with spot-specific salvage lymphnode dissection (sLND) for positron-emission tomography (PET)-positive prostate cancer (PCa) relapse.

Authors:  Andreas Hiester; Alessandro Nini; Günter Niegisch; Christian Arsov; Hubertus Hautzel; Christina Antke; Lars Schimmöller; Peter Albers; Robert Rabenalt
Journal:  World J Urol       Date:  2019-01-14       Impact factor: 4.226

Review 8.  Oligorecurrent prostate cancer limited to lymph nodes: getting our ducks in a row : Nodal oligorecurrent prostate cancer.

Authors:  Andrei Fodor; Andrea Lancia; Francesco Ceci; Maria Picchio; Morten Hoyer; Barbara Alicja Jereczek-Fossa; Piet Ost; Paolo Castellucci; Elena Incerti; Nadia Di Muzio; Gianluca Ingrosso
Journal:  World J Urol       Date:  2018-05-11       Impact factor: 4.226

Review 9.  Surgical resection of urological tumor metastases following medical treatment.

Authors:  Axel Heidenreich; Stefan Wilop; Michael Pinkawa; Daniel Porres; David Pfister
Journal:  Dtsch Arztebl Int       Date:  2012-09-28       Impact factor: 5.594

Review 10.  PET imaging for lymph node dissection in prostate cancer.

Authors:  Elena Incerti; Paola Mapelli; Luigi Gianolli; Maria Picchio
Journal:  World J Urol       Date:  2016-10-17       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.